Electric Royalties (OTC:ELECF) Stock, Quote.Headers.trade-ideas

Electric Royalties Ltd is a royalty company established to take advantage of the demand for a wide range of commodities (lithium, vanadium, manganese, tin, graphite, cobalt, nickel, zinc and copper) that will benefit from the drive toward electrification of a variety of consumer products: cars, rechargeable batteries, large scale energy storage, renewable energy generation and other applications.

Penny Stocks

ELECF

WCUFF

TSXV:WCU

TSXV:ELEC


  By Steven Ralston, CFA

OTC:WCUFF | TSXV:WCU

READ THE FULL WCUFF RESEARCH REPORT

WCUFF: World Copper Limited Plans Drilling Exploration Programs at Escalones in Chile &amp; Zonia in Arizona in 2nd Half of 2022; Restructuring Zonia Royalties Provides US$2.6 million in Cash. Gross Proceeds of 1st Tranche of Placement Approximately CDN$1.28 million

ELECTRIC ROYALTIES LTD by Electric Royalties Ltd.

Electric Royalties Ltd

GLMD: 60% &#x7C; <a href="https://www.benzinga.com//node/40935862">Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years</a>
&nbsp;
EWTX: 42% &#x7C; <a href="https://www.benzinga.com//node/40935611">Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy</a>
&nbsp;
XCUR: 271% &#x7C; <a href="https://www.benzinga.com//node/40927738">Exicure shares are trading higher after the company announced it received an extension from the Nasdaq Hearings Panel.</a>

Movers

Trading Ideas

EWTX

GLMD

XCUR

Market-Moving News for September 19th

TD Cowen analyst Andrew Charles reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Hold and maintains $150 price target.

News

Price Target

Reiteration

Analyst Ratings

TD Cowen Reiterates Hold on Darden Restaurants, Maintains $150 Price Target

Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares came under pressure <a href="https://www.benzinga.com/tech/24/09/40930388/apple-iphone-16-pre-orders-show-possible-low-demand-one-sign-could-point-to-company-breaking-this-em">following commentary about demand immediately after pre-orders began </a>but a bullish analyst explained on Wednesday why the early trends should not be a cause for worry.
The Apple Analyst: Morgan Stanley analyst Erik Woodring has an Overweight rating and a $273 price target for Apple.
The Apple Thesis: iPhone 16 lead times have doubled from last Friday and have been longer internationally than in the U.S., but it is still tracking lower year-over-year, said Woodring in a note. As of Sept. 17, four days after preorders started:
<ul>
<li>The U.S. lead time is 14.4 days, up 100% from last Friday;</li>
<li>But lower than the 21.6-day average for all iPhone 15 models during the same period last year;</li>
<li>And 18-day average for all iPhone 14 models four days after preorders started in 2022.</li>
</ul>
Morgan Stanley&#8217;s tracking model going back to 2017 showed there is a directional, positive relationship between average lead times in the first two weeks after preorders began and the strength of iPhone shipments over the 12 months, Woodring said. &#8220;The longer the average lead time in the first two weeks after pre-orders begin, generally, the stronger the next 12-month shipments are for that specific iPhone model,&#8221; he said. 
That said, no strong correlation exists when comparing new iPhone model lead times in the first two weeks until the December quarter and total shipments over the next 12 months, the analyst said. &#8220;This is because lead times are influenced by both supply and demand, making iPhone lead times as a proxy this early in the cycle not yet truly informative,&#8221; he said.
See Also: <a href="https://www.benzinga.com/money/best-tech-stocks">Best AI Stocks Right Now</a>
According to the analyst, the shorter lead times this time around could be due to:
<ul>
<li>Apple directing the supply chain to build 5% more iPhone 16s in the second half of the calendar year 2024 than iPhone 15s during the comparable period in 2023;</li>
<li>The key reason for upgrading to the iPhone 16, <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">Apple Intelligence features,</a> may not be available in the U.S. until October. In the U.K. it would be available only later this year, and the Chinese and Japanese customers get those only next year. This could be delaying upgrades, Woodring said.</li>
</ul>
The Apple Stock: Looking at stock implications, Woodring said at $216, Apple traded at a relatively full 29 times Morgan Stanley&#8217;s 2025 earnings per share estimate of $7.50. Any near-term outperformance from here would have to come from a growth acceleration/positive earnings revisions, he said. 
That said, the analyst noted that the December quarter iPhone builds have been revised lower by 3-6 million units over the last decade. Every one million iPhone build reduction equates to 4-cent earnings per downside, with Apple&#8217;s price/earnings multiple contracting by 1.5 times, on average, in the three months after an iPhone launch, he said.
The analyst sees downside support for the stock around $197, which translates to $7.30 per share in earnings per share and 27 times multiple. 
But most bulls see the fiscal year 2026 and the iPhone 17 as the bigger cycle and any estimate cuts or near-term stock underperformance will likely get bought, leading to just a short window of underperformance before investors turn their attention to the iPhone 17 and FY26 earnings power, he said.
In premarket trading, Apple shares climbed 1.62% at $224.27, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40914325/apple-stock-reaction-after-iphone-launch-sparks-portfolio-managers-reflection-i-may">Apple Stock Reaction After iPhone Launch Sparks Portfolio Manager&#8217;s Reflection: &#8216;I May Be Wrong In The Short Term But&#8230;Will Be Back In The Long Run&#8217;</a></li>
</ul>
Image via Unsplash

Analyst Color

Equities

Tech

AAPL

Apple Analyst Shrugs Off Lukewarm Early iPhone 16 Demand Trends: Here's Why Soft Preorder Data Hasn't Dented Morgan Stanley's Bullish Thesis

Enables Qualifying Customers to Use HSA (Health Savings Account) or FSA (Flex Savings Account) Funds to Purchase BODi Nutritional Supplements and Fitness Offerings
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fthebeachbodycompany.com%2F&amp;esheet=54123782&amp;newsitemid=20240919616045&amp;lan=en-US&amp;anchor=The+Beachbody+Company%2C+Inc.&amp;index=1&amp;md5=a68ffec7f8eedd2d6d2930e2cd127850">The Beachbody Company, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) ("BODi"), a leading fitness and nutrition company, announced today a strategic partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.truemed.com%2F&amp;esheet=54123782&amp;newsitemid=20240919616045&amp;lan=en-US&amp;anchor=Truemed&amp;index=2&amp;md5=acec2721783fbebd5219ef6637be2923">Truemed</a>, a leading healthcare payment provider that helps qualified customers spend their HSA/FSA funds on supplements, exercise and other lifestyle interventions that can help treat or prevent chronic disease. The partnership enables qualifying BODi customers to use their pre-tax HSA or FSA money to pay for supplement purchases from BODi's best-in-class product portfolio, including its Shakeology superfood nutrition shakes. By using pre-tax income for purchases, BODi customers can access their supplements at a significant discount.
To access the partnership, current and new BODi customers can take an online medical assessment with Truemed to determine if they qualify for a Letter of Medical Necessity (LMN). If approved, the LMN is valid on all supplement purchases for a year and allows customers to save up to 40% on BODi supplements, including both one-time and monthly subscription purchases.

The Beachbody Company, Inc. Class A Common Stock

BODI

BODi And Truemed Partner To Provide Pre-Tax Reimbursement For BODi Health And Fitness Supplements

Biotech

General

AEMD

Aethlon Receives Ethics Committee Approval For Hemopurifier Cancer Trial In India, Targeting Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy

Piper Sandler analyst Patrick Moley maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Overweight and raises the price target from $23 to $27.

HOOD

Piper Sandler Maintains Overweight on Robinhood Markets, Raises Price Target to $27

<a href="https://www.globenewswire.com/Tracker?data=IOZSQF7l2NlW9dojiDWx9HMQptoABpF2Il4ywCXA5XTPitneEGZNU0z2MWDTAUvxuelopl_woOJhmiPtw5Rn-w==">CorMedix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath&#xAE; (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics located across the United States. &nbsp;
CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare &amp; Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders to outpatient dialysis facilities in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the beginning of the fourth quarter.

CRMD

CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States

AIM ImmunoTech Announces Prelim. Data From Phase 1b/2 Study Of Ampligen And Imfinzi; Says 'Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort'

AMZN

NTAP

NetApp Signs Strategic Collaboration Agreement With AWS To Enhance Cloud-Based Data Services, Accelerate Generative AI Efforts, And Drive CloudOps Value

Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.10 by 10.91 percent. This is a 45.25 percent decrease over earnings of $1.79 per share from the same period last year. The company reported quarterly sales of $894.39 million which missed the analyst consensus estimate of $897.22 million by 0.32 percent. This is a 6.89 percent increase over sales of $836.73 million the same period last year.

Earnings

Earnings Misses

CBRL

Cracker Barrel Old Q4 Adj $0.98 Misses $1.10 Estimate, Sales $894.39M Miss $897.22M Estimate

EVAX

Evaxion Announces An Update Of Its EDEN AI Prediction Model, Featuring A Novel Toxin Antigen Predictor

<a href="https://www.globenewswire.com/Tracker?data=5jgK2-b8x7-bCcNdJPov_gm8LWrdhiPzE6BWpC5q-uC-832qloMe-mb-28Azf_hgW4HcdAKMAutKNMZzjx5f_Q==">LifeMD, Inc.</a><a href="https://www.globenewswire.com/Tracker?data=51jmIb3lT-TliDCB6Db_FvWaAdiE7waFYPNh9AQXPaK9kK2GmIJYglyXC2C4YkfU">&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>), a leading provider of virtual primary care services, today announced significant enhancements to its weight management program, underscoring the company's commitment to expanding patient access and improving the quality and comprehensiveness of care available on its virtual care platform. The investments include a new and improved platform and partnership for in-home lab collection, technology enhancements for prior authorization and pharmacy benefits infrastructure, and the launch of personalized prescription treatment options. These advancements further establish LifeMD as a leader in the rapidly growing market for virtual healthcare.
As part of its commitment to increasing access to branded prescription GLP-1 medications, LifeMD has developed and is launching a real-time electronic benefit verification program that allows patients to check pharmacy benefits verification before enrolling in a LifeMD virtual care program. Additionally, LifeMD has partnered with an AI-powered platform that optimizes prior authorization submissions and appeals to improve approval rates for patients. These enhancements are designed to minimize delays in care, reduce barriers to accessing brand-name medications, and ensure that a broader range of patients can benefit from LifeMD's offerings.

LFMD

LifeMD Announces Enhancements To Its Weight Management Program, Expanding Patient Access To Branded GLP-1 Therapies And Introducing New Treatment Options

HUMA

Humacyte Announces U.S. Patent Allowance For BioVascular Pancreas (BVP), Supporting Potential Treatment For Type 1 Diabetes

New Nano-Grid System '<a href="https://www.globenewswire.com/Tracker?data=WkyeP-xg0-zKIG1giac2fw17vDet6ffDyr7K78Hfhf2qReoNiyhFk_aavxtK-Y3Uo0ux0oMZeapoRCs3puOvKNFODEtf8JisTS4Bd1BN7fs=">SOLIS' and 'COR'</a> Stores 4,000Wh or more of Clean Energy Daily, Offering Modular, Portable Power Solutions for Vehicles, Jobsites, First Responders, Military, and Outdoor Enthusiasts. &nbsp;
West Seneca, New York, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) ("Worksport" or the "Company"), a U.S.-based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, is excited to announce a major update on its innovative, much anticipated, nano-grid system, known as "SOLIS &amp; COR." This system includes the SOLIS solar tonneau cover and the COR portable energy system. The plan to bring this system to market is strategically arranged in three phases: Alpha release, Beta release, and full-scale market launch. The Alpha release phase has been initiated, with approximately 100 systems set for rigorous testing and public exposure during this initial market release.

WKSP

Worksport Initiates Alpha Launch Of Solis Solar Array And COR Mobile Battery Power Generator; New Nano-Grid System 'SOLIS' And 'COR' Stores 4,000Wh Or More Of Clean Energy Daily, Offering Modular, Portable Power Solutions For Vehicles, Jobsites, First Responders, Military, And Outdoor Enthusiasts

PGNY

Progyny Late Wednesday Said A Client Elected To Exercise A 90-Day Option To Terminate Its Services Agreement With The Company, Effective Jan. 1

Throughout the last three months, 4 analysts have evaluated Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.75, along with a high estimate of $53.00 and a low estimate of $37.00. A decline of 7.41% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747277_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Staar Surgical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$37.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Staar Surgical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Staar Surgical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>A Deep Dive into Staar Surgical's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 7.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Staar Surgical's net margin excels beyond industry benchmarks, reaching 7.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Staar Surgical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.47%, the company showcases effective utilization of assets.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STAA

Analyst Scoreboard: 4 Ratings For Staar Surgical

WIIM

Carnival shares are trading higher after Mizuho maintained an Outperform rating on the stock and raised its price target from $22 to $25.

4 analysts have expressed a variety of opinions on Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Kosmos Energy, presenting an average target of $6.5, a high estimate of $8.00, and a low estimate of $5.00. A 15.25% drop is evident in the current average compared to the previous average price target of $7.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747264_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Kosmos Energy among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$5.00</td>
<td>-</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Bob Brackett</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Kosmos Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kosmos Energy compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Kosmos Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Kosmos Energy analyst ratings.</a>
<h2>Delving into Kosmos Energy's Background</h2>
Kosmos Energy Ltd is an independent oil and gas exploration and production company focused on frontier and emerging areas along the Atlantic Margin. The company focuses on field developments designed to accelerate production. Kosmos' exploration is tied to a geologically based approach geared toward the identification of petroleum systems. Its process starts with geologic studies that assess a region's subsurface but also incorporates basin modeling as well as techniques to identify reservoir/seal pair development and trap definition. In addition, a 3D seismic analysis is done to identify prospective traps of interest. In tandem with the subsurface analysis, a country-specific analysis is done to get an understanding of above-ground dynamics before targeting specific licenses.
<h3>Kosmos Energy: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Kosmos Energy's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 65.01%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Kosmos Energy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kosmos Energy's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Kosmos Energy's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.11%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Kosmos Energy's debt-to-equity ratio stands notably higher than the industry average, reaching 2.27. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 4 Analyst Insights On Kosmos Energy

5 analysts have shared their evaluations of SS&amp;C Techs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $83.6, along with a high estimate of $90.00 and a low estimate of $75.00. This current average reflects an increase of 7.46% from the previous average price target of $77.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747249_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of SS&amp;C Techs Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SS&amp;C Techs Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SS&amp;C Techs Hldgs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of SS&amp;C Techs Hldgs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of SS&amp;C Techs Hldgs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SSNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on SS&amp;C Techs Hldgs analyst ratings.</a>
<h2>Delving into SS&amp;C Techs Hldgs's Background</h2>
SS&amp;C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&amp;C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&amp;C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&amp;C's purchase of Intralinks makes it a leading player in Virtual Data Room solutions. With its 2018 purchase of DST Systems, SS&amp;C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&amp;C completed the acquisition of Blue Prism.
<h3>SS&amp;C Techs Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: SS&amp;C Techs Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.52%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): SS&amp;C Techs Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 2.96%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): SS&amp;C Techs Hldgs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.11%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SSNC

In-Depth Examination Of 5 Analyst Recommendations For SS&C Techs Hldgs

Analysts' ratings for Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.8, along with a high estimate of $24.00 and a low estimate of $14.00. This current average represents a 11.86% decrease from the previous average price target of $21.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747238_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Talos Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Talos Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Talos Energy compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Talos Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Talos Energy's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TALO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Talos Energy analyst ratings.</a>
<h2>Discovering Talos Energy: A Closer Look</h2>
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
<h3>Talos Energy: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Talos Energy displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 49.55%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Talos Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.25%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.45%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.53, Talos Energy adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TALO

Expert Outlook: Talos Energy Through The Eyes Of 5 Analysts

Electric Royalties Ltd. (TSE:ELEC) has released an update. Electric Royalties Ltd. has announced the acquisition of a significant lithium royalty a...

Electric Royalties Expands Lithium Holdings

Electric Royalties to acquire lithium royalty and option portfolio

Electric Royalties Ltd. (TSE:ELEC) has released an update. Electric Royalties Ltd. has finalized the acquisition of a significant lithium royalty a...

Electric Royalties Expands Lithium Holdings in Ontario

Electric Royalties (TSE:ELEC) has released an update. Electric Royalties has announced significant progress with its diverse royalties in lithium, ...

Electric Royalties Eyes Growth with Diverse Portfolio

Electric Royalties (TSE:ELEC) has released an update. Electric Royalties Ltd. has announced that Gleason & Sons LLC will convert over half a millio...

Electric Royalties Converts Debt to Equity

Electric Royalties (TSE:ELEC) has released an update. Electric Royalties Ltd. reports progression in its diverse mining interests, including antici...

Electric Royalties Anticipates Growth Amid Advances

Electric Royalties (TSE:ELEC) has released an update. Electric Royalties Ltd. has announced that Gleason & Sons LLC will convert over C$217,000 of ...

Electric Royalties Converts Debt to Equity Amidst Growth

Electric Royalties (TSE:ELEC) has released an update. Electric Royalties Ltd., a company capitalizing on the demand for various commodities essenti...

Electric Royalties Boosts Market Presence with Red Cloud

Electric Royalties (TSE:ELEC) has released an update. Electric Royalties Ltd. reports a substantial increase in the copper resources at the Zonia P...

Electric Royalties Touts Zonia Project's Growth

Electric Royalties (TSE:ELEC) has released an update. Electric Royalties Ltd. has entered into an agreement to purchase a cash-flowing copper strea...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Electric Royalties

Electric Royalties (ELECF) Forecast

Electric Royalties (OTC:ELECF) Stock, Quote.Headers.trade-ideas